Notice of Proposed Sale · 144
Dyne Therapeutics, Inc.
DYNNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Dyne Therapeutics, Inc.
- Issuer CIK
- 0001818794
- SEC file number
- 001-39509
- Phone
- 7817868230
- Person for whose account securities are to be sold
- Atlas Venture Fund XI, LP
- Relationships to issuer
- Shareholder
- Street
- 1560 Trapelo Road
- City
- Waltham
- State / country code
- MA
- Postal code
- 02451
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,359,674 | 35,297,137.04 | 186,746,431 | 08/14/2026 | Nasdaq | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 555 California Street
- Street (continued)
- 18th Floor
- City
- San Francisco
- State / country code
- CA
- Postal code
- 94104
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/31/2020 | Private Placement | Issuer | 1,359,674 | N | 07/31/2020 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Please see attached for securities sold over the last 3 months
Notice signature
- Notice date
- 08/14/2026
- Signed
- Ommer Chohan
- Plan adoption dates
- 07/13/2026
Filed exhibits
- EX-99 ↗dyn_tableiix20260814.pdf
Company context
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.